Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 20/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20189354 | 1.00 | GRIN2B (0.61) | GRIN2BCYP2D6CYP2C9KCNH2CYP3A4 | |
| SCHEMBL21404310 | 1.00 | GRIN2B (0.61) | GRIN2BCYP2D6CYP2C9KCNH2CYP3A4 | |
| SCHEMBL20189929 | 0.97 | GRIN2B (0.60) | GRIN2BCYP2D6CYP2C9KCNH2CYP3A4 | |
| SCHEMBL20190519 | 0.97 | GRIN2B (0.60) | GRIN2BCYP2D6CYP2C9KCNH2CYP3A4 | |
| SCHEMBL20203014 | 0.90 | GRIN2B (0.64) | GRIN2BCYP2D6CYP2C9KCNH2CYP3A4 | |
| SCHEMBL20189724 | 0.90 | GRIN2B (0.64) | GRIN2BCYP2D6CYP2C9KCNH2CYP3A4 | |
| SCHEMBL20202821 | 0.90 | GRIN2B (0.64) | GRIN2BCYP2D6CYP2C9KCNH2CYP3A4 | |
| SCHEMBL20202823 | 0.89 | GRIN2B (0.77) | GRIN2BCYP2D6CYP2C9KCNH2 | |
| SCHEMBL20189296 | 0.89 | GRIN2B (0.77) | GRIN2BCYP2D6CYP2C9KCNH2 | |
| SCHEMBL21404311 | 0.89 | GRIN2B (0.77) | GRIN2BCYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527799-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2026-01-20 | — | — | US | disclosed |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2024-06-27 | — | — | US | disclosed |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2023-09-12 | — | — | US | disclosed |
| US-20210220365-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-07-22 | — | — | US | disclosed |
| US-11000526-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-05-11 | — | — | US | disclosed |
| US-20190298725-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-10-03 | — | — | US | disclosed |
| WO-2018098128-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000526-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | GRIN2B 3/4885CYP2D6 3997/4885CYP2C9 3374/4885 |
| US-20190298725-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | GRIN2B 3/4885CYP2D6 3997/4885CYP2C9 3374/4885 |
| US-20210220365-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | GRIN2B 3/4885CYP2D6 3997/4885CYP2C9 3374/4885 |
| US-12527799-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2C, GRIN3A, GRIN1 | GRIN2B 8/4885CYP2D6 2168/4885CYP2C9 2840/4885 |
| US-11752155-B2 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | GRIN2A, GRIN1, GRIN2B | GRIN2B 3/4885CYP2D6 3997/4885CYP2C9 3374/4885 |
| US-20240207273-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | GRIN2A, GRIN1, GRIN2B | GRIN2B 3/4885CYP2D6 3997/4885CYP2C9 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.